Latest market headlines for SYMBIOTEC on Terminal.
06-Nov-2026 11:19:47
SYMBIOTEC PHARMALAB Q2 FY27 CONCALL: GUIDES 20% FY27 REVENUE GROWTH & 25% EBITDA GROWTH; TARGETS 30–40% CDMO EBITDA MARGINS, Q1 FY28 US ALT-PROTEIN COMMERCIALI…
06-Nov-2026 10:20:44
• Long-Term Agreement: Signed a 10-year take-or-pay manufacturing agreement with a European alternative protein innovator • Business Diversification: Expanding…
06-Nov-2026 09:54:55
• 10-year take-or-pay contract development and manufacturing agreement reserves dedicated capacity for the partner at Symbiotec's Ujjain campus for the full te…
05-Nov-2026 19:49:21
REVENUE UP 43.18% AT ₹279.93 CR (YOY), UP 28.32% (QOQ) EBITDA UP 81.99% AT ₹91.51 CR (YOY), UP 102.47% (QOQ) MARGINS AT 32.69% VS 25.72% (YOY), 20.72% (QOQ)
30-Sept-2026 20:11:44
• Symbiotec's wholly owned subsidiary Knovea Pharmaceutical entered into a strategic commercialization agreement with a leading global pharmaceutical company f…
29-Sept-2026 10:53:10
• Symbiotec Pharmalab Limited has received the Establishment Inspection Report (EIR) from the U.S. FDA for its manufacturing facility in Pithampur, Madhya Prad…
21-Sept-2026 19:52:26
• Consolidated revenues stood at ₹218.2 Cr vs ₹203.2 Cr (YOY). • Consolidated EBIDTA was ₹45.2 Cr vs ₹58.0 Cr (YOY). • Consolidated PAT stood at ₹14.1 Cr vs ₹2…
21-Sept-2026 18:47:12
• The board of directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. • The trading window for dea…